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Replication of initial genome-wide association findings is consid-
ered a gold standard for reporting genotype–phenotype associa-
tions. Three human genomic regions at chromosomes 15q25, 5p15, 
and 6p21 that were found to be associated with susceptibility to lung 
cancer in genome-wide association studies merit such replication.
The region at 15q24–25.1, which contains three nicotinic ace-
tylcholine receptor subunit genes (CHRNA5, CHRNA3, and 
CHRNB4), was associated with the risk of lung cancer in three 
independently conducted genome-wide association studies that 
gave remarkably consistent results for associations between three 
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 Background Genome-wide association studies have identified three chromosomal regions at 15q25, 5p15, and 6p21 as being 
associated with the risk of lung cancer. To confirm these associations in independent studies and investigate 
heterogeneity of these associations within specific subgroups, we conducted a coordinated genotyping study 
within the International Lung Cancer Consortium based on independent studies that were not included in pre-
vious genome-wide association studies.
 Methods Genotype data for single-nucleotide polymorphisms at chromosomes 15q25 (rs16969968, rs8034191), 5p15 
(rs2736100, rs402710), and 6p21 (rs2256543, rs4324798) from 21 case–control studies for 11 645 lung cancer case 
patients and 14 954 control subjects, of whom 85% were white and 15% were Asian, were pooled. Associations 
between the variants and the risk of lung cancer were estimated by logistic regression models. All statistical 
tests were two-sided.
 Results Associations between 15q25 and the risk of lung cancer were replicated in white ever-smokers (rs16969968: 
odds ratio [OR] = 1.26, 95% confidence interval [CI] = 1.21 to 1.32, Ptrend = 2 × 10226), and this association was 
stronger for those diagnosed at younger ages. There was no association in never-smokers or in Asians between 
either of the 15q25 variants and the risk of lung cancer. For the chromosome 5p15 region, we confirmed statis-
tically significant associations in whites for both rs2736100 (OR = 1.15, 95% CI = 1.10 to 1.20, Ptrend = 1 × 10210) 
and rs402710 (OR = 1.14, 95% CI = 1.09 to 1.19, Ptrend = 5 × 1028) and identified similar associations in Asians 
(rs2736100: OR = 1.23, 95% CI = 1.12 to 1.35, Ptrend = 2 × 1025; rs402710: OR = 1.15, 95% CI = 1.04 to 1.27, Ptrend = 
.007). The associations between the 5p15 variants and lung cancer differed by histology; odds ratios for 
rs2736100 were highest in adenocarcinoma and for rs402710 were highest in adenocarcinoma and squamous 
cell carcinomas. This pattern was observed in both ethnic groups. Neither of the two variants on chromosome 
6p21 was associated with the risk of lung cancer.
 Conclusions In this international genetic association study of lung cancer, previous associations found in white populations 
were replicated and new associations were identified in Asian populations. Future genetic studies of lung can-
cer should include detailed stratification by histology.
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single-nucleotide polymorphisms (SNPs) at this locus and the risk 
of lung cancer: The MD Anderson Cancer Center study reported 
an odds ratio (OR) of 1.32 (P = 10217) for rs8034191 (1), the 
International Agency for Research on Cancer (IARC) study (2) 
reported an odds ratio of 1.30 (P = 10220) for rs8034191 and 
rs16969968, and the deCODE study reported an odds ratio of 1.31 
(P = 1028) for rs1051730 (3). All of these three SNPs (rs8034191, 
rs16969968, and rs1051730) are in strong linkage disequilibrium.
Subsequent meta-analyses identified another putative causative 
region at 5p15.33 (4,5). This region contains two genes: the 
human telomerase reverse transcriptase gene (TERT) and cleft lip 
and palate transmembrane 1–like gene (CLPTM1L). The IARC (4) 
and the Institute of Cancer Research (ICR) and MD Anderson 
groups (5) reported that two different SNPs at 5p15.33 (rs402710 
and rs401681, respectively), which are in strong linkage disequilib-
rium (D′ = 1.00, r2 = .66), are associated with the risk of lung cancer 
(IARC study: P = 2 × 1027; ICR and MD Anderson groups: P = 8 × 
1029). The IARC group also identified a second SNP, rs2736100, 
that was associated with the risk of lung cancer (P = 4 × 1026). A 
report from the deCODE group (6) provided evidence that the 
cONteXt AND cAVeAtS
Prior knowledge
Genome-wide association studies that were conducted in white 
populations have identified three chromosomal regions at 15q25, 
5p15, and 6p21 as being associated with the risk of lung cancer. 
Whether genetic variants at these regions are associated with risk 
of lung cancer in other populations is unclear.
Study design
A coordinated genotyping study of six single-nucleotide polymor-
phisms at these three chromosomal regions using data from 21 
independent case–control studies that included Asians studies and 
were not included in previous genome-wide association studies.
Contribution
The 15p25 locus–risk of lung cancer association in whites was rep-
licated, but there was no association between this locus and the 
risk of lung cancer in white lifetime never-smokers. There was no 
association between 15q25 and the risk of lung cancer in Asians. 
The chromosome 5p15 locus–risk of lung cancer association was 
replicated in whites, and a similar association was found in Asians. 
In both whites and Asians, the two variants in 5p15 were more 
strongly associated with adenocarcinoma than with other his-
tology groups. Chromosome 6p21 was not associated with the risk 
of lung cancer.
Implications
Future genetic studies of lung cancer should include detailed strat-
ification by histology.
Limitations
Some of the variants at chromosome 15q25 had low minor allele 
frequencies in Asians. Replication of variants in Asians that were 
originally identified in studies of whites may not be relevant. The 
fact that different studies with different genotyping protocols were 
included could have led to heterogeneity.
From the Editors
 
5p15.33 region may be a susceptibility locus for multiple cancer 
types and also reported associations between risk of lung cancer 
and two potential susceptibility alleles.
The third region that has been implicated by genome-wide as-
sociation studies in susceptibility to lung cancer is the HLA region 
at chromosome 6p21. Hung et al. (2) presented evidence for an 
association between the SNP rs4324798 at 6p21 and the risk of 
lung cancer (P = 4 × 1027). Wang et al. (5) identified two other 
SNPs that were statistically significantly associated with risk of 
lung cancer and that mapped to this region: rs3117582 (P = 5 × 
10210) and rs9295740 (P = 4 × 1027).
We aimed to replicate these findings in a large sample size 
dataset because there is still no consensus about the relative impact 
with respect to risk of lung cancer of the chromosome 15q25 locus 
on smoking behavior vs a direct lung carcinogenic effect. In addi-
tion, the newly identified susceptibility loci on 5p15 and 6p21 
require further investigation in a larger sample size and in different 
ethnic groups. It is also important to evaluate effect modification 
by sex, age at cancer diagnosis, and family history, as well as by 
histological classification.
The International Lung Cancer Consortium (ILCCO) was 
established in 2004 with the aim of sharing comparable data from 
ongoing case–control and cohort studies of lung cancer. The over-
all objectives of the consortium are to share the data to increase 
statistical power, especially for subgroup analyses, reduce duplica-
tion of research efforts, replicate novel findings, and realize sub-
stantial cost savings through large collaborative efforts. Details of 
how the consortium was established have been published previ-
ously (7). With the aim of replicating association findings concern-
ing these variants and the risk of lung cancer with sufficient 
statistical power for analysis of specific subgroups, we invited the 
principle investigators of all case–control studies from ILCCO to 
conduct genotyping of their lung cancer case patients and control 
subjects of European and Asian ancestry for two variants at the 
15q25 locus (rs8034191 and rs16969968), two variants at 5p15 
(rs402710 and rs2736100), and two variants at 6p21 (rs4324798 
and rs2256543, the latter of which was the second most statistically 
significant SNP on chromosome 6 from the IARC genome-wide 
association study). For studies that were conducted in Asian popu-
lations, we selected three additional variants in the 15q25 region 
for genotyping (rs12914385, rs1317286, and rs931794) and the 
variants in 6p21 were not genotyped because of their low preva-
lence in these populations (according to the HapMap genome 
browser, www.hapmap.org).
Materials and Methods
Study Population
Twenty-one of the 52 case–control studies from the ILCCO par-
ticipated in this pooled analysis. Of these studies, nine were con-
ducted in North America, eight in Europe, and four in Asia. The 
study designs are briefly outlined in Table 1, and some of them 
have been described in more detail previously (6,8–19). The 
studies are referred to here either by the study location or the 
name of the coordinating institution.
The Singapore study included only women; the MD Anderson, 
Norwegian, and French studies included only ever-smokers. All 
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studies had detailed information on histology that was based on 
International Classification of Diseases codes or pathology reports. 
All studies included incident cases of lung cancer. In most of the 
studies, the control subjects were frequency matched to the case 
patients on age and sex; some studies also matched on ethnicity 
(Hawaii and Canadian studies), place of residence (UCLA study), or 
smoking status (Norway and MD Anderson studies). Written 
informed consent was obtained from all study subjects, and the 
investigations were approved by the institutional review boards at 
each study center. Only individuals who reported white or Asian 
ethnicity were included in this analysis of 11 645 lung cancer case 
patients and 14 954 control subjects, of whom 85% were white and 
15% were Asian (Table 1).
Genotyping and Quality Control
Genotyping from genomic DNA isolated from blood sample or 
saliva (the extraction technique for each center is available upon 
request) was performed locally at the participating centers using 
TaqMan probes (Applied Biosystems, Foster City, CA) (probe and 
primer sequences are provided in Supplementary Table 1 [avail-
able online]) that were supplied by IARC with the following excep-
tions: Two studies (Toronto and France) used genotyping data 
that were obtained from HumanHap300 BeadChips (Illumina, San 
Diego, CA), the German multicenter and Saarland studies used the 
iPLEX assay (Sequenom, San Diego, CA), and two studies (Spain 
and the Netherlands) performed genotyping with the use of the 
Centaurus platform (Nanogen, San Diego, CA). All genotyping 
assays were performed according to the manufacturer’s protocol. 
The quality of the Centaurus assays was evaluated by genotyping 
each assay in the HapMap CEU sample, which comprises Utah 
residents with ancestry from Northern and Western Europe 
(www.hapmap.org), and comparing the results with the HapMap 
publicly released data. Assays with a mismatch rate greater than 
1.5% were not included in the statistical analysis. Standardized 
quality control procedures were applied in all centers that used 
TaqMan or iPLEX assays: Each center genotyped a generic series 
of 90 standard DNA samples (from either the HapMap CEU 
sample or a generic series from IARC) in their local genotyping 
facility. The genotype concordance across studies was subse-
quently computed for each genotyping assay. When more than 
one discrepancy between the genotypes obtained from the local 
genotyping technique and the HapMap publicly available geno-
types or the IARC generic series genotypes for a variant was found 
in a study, that study was excluded from the analysis of that variant 
(Supplementary Table 2, available online). The average genotype 
completion rate per SNP varied from 97.1% to 99.6% in the 
pooled data, and all genotype completion rates per study were 
greater than 90% for each variant.
We used a x2 test with 1 df to verify that the allele distributions 
for each SNP were in Hardy–Weinberg equilibrium within each 
study and separately among white control subjects and Asian con-
trol subjects. A Bonferroni correction for multiple tests was ap-
plied for the Hardy–Weinberg equilibrium test and gave a P value 
of .0005 as the cutoff for statistical significance (based on approxi-
mately 100 independent tests carried out). No deviation from 
Hardy–Weinberg equilibrium was observed (Supplementary Table 3, 
available online).
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Statistical Analysis
We used unconditional logistic regression to estimate odds ratios 
and 95% confidence intervals (CIs). The heterozygous and ho-
mozygous carriers of the risk allele were each compared with the 
homozygous carriers of the nonrisk allele. Odds ratios per allele 
or P values for trend were calculated by assuming a log-additive 
genetic model with 1 df. Pooled odd ratios were calculated using 
individual-level data. Information on demographic variables (age, 
sex, ethnicity), tobacco exposures, family history of cancer, and 
histology classification (for case patients) was available. Mean 
numbers of cigarettes smoked per day were derived from analysis 
of variance and are adjusted for age, sex, study, and case–control 
status when appropriate. Ethnicity was self-declared, and only 
subjects who declared themselves to be white or Asian were in-
cluded in the analysis. Whites and Asians were analyzed sepa-
rately. Models were adjusted for potential confounders, including 
age, sex, study center, and, where appropriate, cumulative to-
bacco consumption (expressed as pack-years). To evaluate effect 
modification, we conducted analyses stratified by smoking status 
(never, former, current), smoking quantity (by 10-pack-year cat-
egories), sex, age at lung cancer diagnosis (by 10-year age 
groups), or family history of cancer among first-degree relatives. 
We also analyzed associations between genetic variants and the 
risk of lung cancer by major histological subtypes (squamous cell 
carcinoma, adenocarcinoma, small-cell carcinoma, and large-cell 
carcinoma). Heterogeneity of odds ratios across the studies and 
across the stratification groups was assessed by using the Cochran 
Q test.
All analyses were conducted with SAS software (version 9.1; 
SAS Institute, Cary, NC). All statistical tests were two-sided, and 
statistical significance required a P value of .05 or less.
Table 2. Distribution of selected demographic variables by ethnic group*
Variable
Whites Asians
Case patients, No. (%) Control subjects, No. (%) Case patients, No. (%) Control subjects, No. (%)
Sex
 Male 5741 (58) 7325 (57) 838 (50) 902 (42)
 Female 4210 (42) 5503 (43) 856 (50) 1224 (58)
Age, y
 <50 1252 (13) 2969 (23) 182 (11) 243 (11)
 50–59 2499 (25) 3443 (27) 426 (25) 492 (23)
 60–69 3273 (33) 3859 (30) 565 (33) 679 (32)
 70–79 2451 (25) 2310 (18) 443 (26) 612 (29)
 ≥80 476 (5) 247 (2) 78 (5) 100 (5)
Smoking status
 Never 962 (10) 4136 (32) 674 (40) 1270 (60)
 Former smoker 4125 (41) 4491 (35) 461 (27) 470 (22)
 Current smoker 4644 (47) 3173 (25) 526 (31) 308 (15)
 Former or current 134 (1) 455 (4) 23 (1) 20 (1)
 Missing 86 (1) 573 (5) 10 (1) 58 (3)
Histology
 Adenocarcinoma 3892 (39) — 929 (55) —
 Squamous cell 2370 (24) — 317 (19) —
 Large cell 413 (4) — 96 (6) —
 Small cell 1235 (12) — 109 (6) —
 Other or not specified 2041 (21) — 243 (14) —
Total 9951 12 828 1694 2126
* Numbers of case and control subjects are those included in the analysis. — = not applicable.
results
Among the white subjects, 57% were male, whereas among the 
Asian subjects, a slight majority was female (50% of the case sub-
jects and 58% of the control subjects) (Table 2). We observed a 
higher prevalence of never-smoking lung cancer case patients 
among Asians (40%) than among whites (10%). This difference is 
mainly because of the Singapore study, which included only 
women, of whom 79% were never-smokers.
Table 3 summarizes the pooled estimates of the main effects for 
each variant. In whites, both of the variants at 15q25 were strongly 
associated with the risk of lung cancer and exhibited similar odds 
ratios in heterozygotes, in homozygotes, and per allele. The stron-
gest association of the two variants at 15q25 was for rs16969968 
(OR = 1.26, 95% CI = 1.21 to 1.32, Ptrend = 2 × 10226). We also 
noted associations between the two variants located on chromosome 
5p15 and the risk of lung cancer (rs2736100: OR = 1.15, 95% CI = 
1.10 to 1.20, Ptrend = 1 × 10210; rs402710: OR = 1.14, 95% CI = 1.09 
to 1.19, Ptrend = 5 × 1028). Among the two variants at 6p21, we 
observed a statistically significant association between the wild-
type allele of rs4324798 and the risk of lung cancer among homo-
zygotes (OR = 1.39, 95% CI = 1.04 to 1.87); however, in the 
log-additive model, neither variant on this chromosome was asso-
ciated with the risk of lung cancer. In Asians, the minor allele 
frequencies of rs16969968 and rs8034191 on chromosome 15q25 
were lower than 5% and no association with the risk of lung cancer 
was observed. None of the other variants selected from this region 
was associated with risk of lung cancer in this ethnic group. 
However, for chromosome 5p15, there were statistically signifi-
cant associations between rs2736100 (OR = 1.23, 95% CI = 1.12 to 
1.35, Ptrend = 2 × 1025) and rs402710 (OR = 1.15, 95% CI = 1.04 
to 1.27, Ptrend = .007) and the risk of lung cancer. No statistically 
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significant heterogeneity by study was observed. The study-spe-
cific odds ratios are presented in Supplementary Figures 1 and 2 
(available online).
We conducted stratified analyses of the chromosome 15q25 
variants in whites (Figure 1). Because linkage disequilibrium 
between rs16969968 and rs8034191 was high (D′ = .95, r2 = .88), 
we reported the results only for rs16969968 (results for rs8034191 
were similar and are not shown). Among never-smokers, there was 
no association between rs16969968 and the risk of lung cancer 
(OR = 1.02, 95% CI = 0.91 to 1.14). Among ever-smokers, this 
association was statistically significantly stronger in current 
smokers (OR = 1.39, 95% CI = 1.29 to 1.50) than in former 
smokers (OR = 1.27, 95% CI = 1.18 to 1.37, Pheterogeneity = 1 × 1025). 
We also noted a higher odds ratio in subjects younger than 
50 years compared with older subjects (Pheterogeneity = 9 × 1024). The 
mean age at lung cancer diagnosis was statistically significantly 
higher among homozygous carriers of the common allele than 
among homozygous carriers of the rare allele (62.8 vs 60.7 years, 
difference = 2.1 years, 95% CI = 1.2 to 3.3 years). There were no 
statistically significant differences in the odds ratio estimates by 
histology, pack-years of cumulative tobacco consumption in ever-
smokers, or sex. Among subjects with no missing data for pack-
years and smoking status, the overall odds ratio adjusted for these 
two variables was slightly lower than the unadjusted odds ratio 
(adjusted OR = 1.25, 95% CI = 1.18 to 1.32; unadjusted OR = 1.33, 
95% CI = 1.26 to 1.40). A stratified analysis of rs16969968 by 
family history of lung cancer among first-degree relatives revealed 
no heterogeneity between subjects with and without a family his-
tory of cancer (data not shown).
We also investigated the association between rs16969968 and 
the risk of lung cancer in the context of smoking intensity in whites 
and observed a gene dosage effect with the mean number of ciga-
rettes smoked per day (Table 4). Overall, the mean number of 
cigarettes smoked per day was 20.74 (95% CI = 20.36 to 21.12) 
among homozygous carriers of the common allele and 23.48 (95% 
CI = 22.92 to 24.04) among homozygous carriers of the risk allele. 
Similar trends were observed in case patients and control subjects 
when analyzed separately.
Figure 2 shows the stratified estimates for rs2736100 and 
rs402710 at chromosome 5p15. We observed statistically significant 
heterogeneity by histology for rs2736100 for both whites (P < .001) 
and Asians (P = .01), and the risks of adenocarcinomas and large-cell 
carcinomas were higher than the risks of squamous and small-cell 
carcinomas. We also observed heterogeneity by histology 
for rs402710, with stronger associations for adenocarcinomas 
and large-cell and squamous cell carcinomas than for small-cell 
Figure 1. Stratified analysis of the association between rs16969968 
and the risk of lung cancer in whites. Except for the odds ratios 
(ORs) for heterozygous and homozygous effect, odds ratios and 
95% confidence intervals (CIs) were derived from the per-allele 
model. All models are adjusted for age, sex, and study. P for hetero-
geneity was derived from the Cochran Q test. Squares represent 
odds ratios; size of the square represents inverse of the variance of 
the log odds ratio; horizontal lines represent 95% confidence inter-
vals; diamonds represent summary estimate combining the study-
specific estimates with a random-effects model; solid vertical line 
represents an odds ratio of 1; dashed vertical line represents the 
overall odds ratio.
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carcinomas; however, this heterogeneity was statistically significant 
only in whites (Pheterogeneity = .03). We also observed a sex difference 
for rs2736100, with a stronger association in women than in men 
(Pheterogeneity = .02 for whites and Pheterogeneity = .03 for Asians).
Because a higher proportion of adenocarcinomas is usually more 
frequent in women than in men (in this study, adenocarcinomas were 
diagnosed in 21% of the female case patients vs 15% of the male case 
patients), we stratified the analysis of rs2736100 by histology and by 
sex. For both men and women, the association between the risk of 
lung cancer and rs2736100 remained stronger for adenocarcinomas 
than for other histologies (data not shown). Conversely, when the 
analysis of rs2736100 was restricted to adenocarcinomas, no hetero-
geneity by sex was observed (data not shown).
We also compared patients with a family history of lung cancer 
with patients without a family history of lung cancer and observed 
a statistically significant association between having a family his-
tory of lung cancer and carrying the rare allele of rs2736100 (OR = 
1.16, 95% CI = 1.03 to 1.32, Ptrend = .02). Likewise, the risk of lung 
cancer associated with the variant genotype was higher among 
subjects with a family history (OR = 1.31, 95% CI = 1.16 to 1.48) 
than among those without a family history (OR = 1.14, 95% CI = 
1.06 to 1.23); however, the difference was not statistically signifi-
cant (Pheterogeneity = .06). No evidence of heterogeneity by family 
history was observed for rs402710, and no heterogeneity by age 
group was observed for either chromosome 5p15 variant (data not 
shown). These results did not change after adjustment for smoking 
intensity (pack-years) or smoking status.
Although the physical distance between rs2736100 and rs402710 
on chromosome 5 is approximately 34 kb, the linkage disequilib-
rium between these two variants is low (whites: r2 = .03, D′ = .23; 
Asians: r2 = .04, D′ = .38). We therefore examined the independent 
associations of rs402710 and rs2736100 with the risk of lung can-
cer by adjusting the effect of each variant for the other and found 
that the association remained statistically significant for both vari-
ants (data not shown). Moreover, we calculated the association 
between rs2736100 (C allele) and the risk of lung cancer among 
those who were homozygous for the common allele of rs402710 
(GG genotype) and found an allelic odds ratio of 1.15 (95% CI = 
1.08 to 1.22) in whites and 1.14 (95% CI = 1.00 to 1.30) in Asians. 
Conversely, the allelic odds ratio for rs402710 (G allele) among 
homozygous carriers of rs2736100 (AA genotype) was 1.09 (95% 
CI = 1.00 to 1.19) in whites and 1.15 (95% CI = 0.98 to 1.36) in 
Asians.
When we summed the number of risk alleles for the rs2736100 
and rs402710 genotypes, we found a statistically significant odds 
ratio per risk allele (whites: OR = 1.12, 95% CI = 1.09 to 1.16; 
Asians: OR = 1.15, 95% CI = 1.08 to 1.23) (Table 5).
We also analyzed the risk of lung cancer associated with the 
combined genotypes of rs16969968, rs2736100, and rs402710 in 
whites (Table 6). The odds ratio of lung cancer for homozygous 
carriers of the three risk variants compared with individuals with 
no risk alleles was 2.64 (95% CI = 1.86 to 3.74, P = 4 × 1028).
Discussion
We replicated the results of previous genome-wide association 
studies for associations between the 15p25 locus, which includes the 
a5a3b4 family of nicotinic receptor genes, and the risk of lung can-
cer in whites and obtained an odds ratio of similar magnitude to that 
previously reported. We also confirmed previous reports (1,21) of 
no association between this locus and the risk of lung cancer in white 
lifetime never-smokers. We also observed no association between 
15q25 and the risk of lung cancer in Asians. For the chromosome 
5p15 region, we confirmed the statistically significant association 
with risk of lung cancer in whites reported previously and now 
report an association of similar magnitude in Asians. We also noted 
a stronger association between the two variants in 5p15 and adeno-
carcinoma vs other histology groups for both whites and Asians. We 
did not replicate the association between chromosome 6p21 and the 
risk of lung cancer that was reported by Hung et al. (2).
This replication study in two distinct ethnic groups represents, 
to our knowledge, the largest international effort in lung cancer 
based on independent studies that were not included in previous 
genome-wide association studies. In addition to replicating associ-
ations from the genome-wide association studies in whites, we ex-
panded our analysis to Asian populations because we hypothesized 
that the different genetic architecture and linkage disequilibrium 
structure of Asians might elucidate associations with the putative 
causal variants. The sample size allowed us to analyze individual-
level data and ensured that we had adequate statistical power for 
stratified analyses of associations between variants and the risk of 
lung cancer based on histology, age at lung cancer diagnosis, 
smoking status, smoking quantity, family history of lung cancer, 
and ethnicity.
There is unequivocal evidence that the 15q25 locus is associ-
ated with smoking status and nicotine dependence in whites. 
Table 4. Association between rs16969968 and smoking intensity expressed in cigarettes smoked per day in whites*
Genotype
All subjects Control subjects Case patients
N
Mean no. of cigarettes  
per day (95% CI) N
Mean no. of cigarettes  
per day (95% CI) N
Mean no. of cigarettes 
per day (95% CI)
rs16969968 (CHRNA5)
 GG 5425 20.74 (20.36 to 21.12) 2610 17.99 (17.45 to 18.53) 2815 22.68 (22.14 to 23.22)
 GA 6597 21.85 (21.49 to 22.20) 2701 19.20 (18.67 to 19.78) 3896 23.70 (23.22 to 24.18)
 AA 2039 23.48 (22.92 to 24.04) 746 20.56 (19.68 to 21.44) 1293 25.56 (24.84 to 26.28)
 Ptrend 7 × 10219 6 × 1029 5 × 10212
* Mean numbers of cigarettes smoked per day were derived from analysis of variance and are adjusted for age, sex, study, and case–control status when  
appropriate. Ptrend was derived from a linear regression with log(number of cigarettes per day) as an outcome. All statistical tests were two-sided.  
CI = confidence interval; N = number of subjects included in the analysis.
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Saccone et al. (20) identified this region in a candidate gene study 
that compared nicotine-dependent smokers with nondependent 
smokers who were categorized according to measures derived from 
the Fagerström Test of Nicotine Dependence. Subsequently, 
Berrettini et al. (21) identified the same genetic association 
between chromosome 15q25 and smoking intensity in a compar-
ison of heavy vs light smokers. Finally, in a genome-wide associa-
tion study on smoking quantity and nicotine dependence, 
Thorgeirsson et al. (3) found a statistically significant association 
between the number of cigarettes smoked per day and the 15q25 
locus. Nicotine dependence was also statistically significantly asso-
ciated with the same genetic markers at 15q25. These findings 
were subsequently confirmed by other groups that used correlated 
clinical characteristics, such as smoking quantity and heavy vs light 
smoking groups, in different populations, including community-
based populations and alcohol-dependent subjects (22,23). In a 
genome-wide association study, Caporaso et al. (24) identified 
multiple SNPs that were statistically significantly associated with 
the number of cigarettes consumed per day at a P value less than 
.001. They also combined their 15q25 results with data from the 
three published lung cancer genome-wide association studies and 
found that rs1051730 was highly statistically significantly associ-
ated with the number of cigarettes smoked per day (P = 5 × 10232), 
as was rs8034191 (P = 2 × 10229).
Le Marchand et al. (25) also reported that smokers who carried 
either the rs1051730 or the rs16969968 variant had higher internal 
Figure 2. Stratified analysis of associations between rs2736100 and 
rs402710 and the risk of lung cancer in whites and Asians. Except for 
the odds ratios (ORs) for heterozygous and homozygous effect, odds 
ratios and 95% confidence intervals (CIs) were derived from the per-
allele model. All models are adjusted for age, sex, and study. P for 
heterogeneity was derived from the Cochran Q test. Squares represent 
odds ratios; size of the square represents inverse of the variance of the 
log odds ratio; horizontal lines represent 95% confidence intervals; di-
amonds represent summary estimate combining the study-specific 
estimates with a random-effects model; solid vertical lines represent 
an odds ratio of 1; dashed vertical lines represent the overall odds 
ratio.
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doses of nicotine (nicotine equivalents) and 4-(methylnitrosamino)-
I-(3-pyridyl)-1-butanone (a tobacco-specific carcinogen) per ciga-
rette smoked compared with smokers who did not carry either 
variant, indicating that carriers of these variants not only smoke 
more cigarettes but also smoke more intensely, extracting a greater 
amount of nicotine and carcinogens per cigarette, compared with 
noncarriers. rs16969968 causes an amino acid substitution in the 
neuronal acetylcholine receptor subunit alpha-5. In vitro studies 
by Bierut et al. (26) have shown that in carriers of the risk allele, 
the a4b2a5 receptors exhibit a lower response to an agonist. In a 
sample of 1050 nicotine-dependent case patients and 879 non– 
nicotine dependent control subjects, Saccone et al. (27) reported 
two distinct loci in CHRNA5–CHRNA3–CHRNB4 gene cluster to 
be associated with nicotine dependence.
In this study, we report different results in whites and in Asians 
for the selected variants at chromosome 15q25. In whites, we iden-
tified a statistically significant gene dosage effect with the highest 
reported number of cigarettes smoked per day in both case and 
control subjects who were carriers of the rs16969968 homozygous 
mutant genotype. We found no difference in the association 
between this variant and the risk of lung cancer by histological 
subtype, sex, or number of pack-years smoked, although current 
smokers exhibited a slightly higher risk of lung cancer compared 
with former smokers. However, we did note that the highest over-
all risk between rs16969968 and the risk of lung cancer was among 
patients who were diagnosed before the age of 50 years. This 
finding confirm previous observations from the MD Anderson 
genome-wide association study that risk estimates for subjects who 
carried the variant genotype were higher for younger patients and 
that carriers of the variant genotype exhibited earlier age at lung 
cancer diagnosis than noncarriers (22). This inverse trend with age 
may argue for a direct role of this region in lung carcinogenesis. 
However, in this study, among the 922 white patients who had 
never smoked, there was no evidence of any association between 
rs16968869 and the risk of lung cancer, suggesting that active 
smoking is a necessary cofactor for lung carcinogenesis.
In Asians, we observed no association between the five variants 
at 15q25 and the risk of lung cancer or the number of cigarettes 
smoked per day. The lower minor allele frequency of rs16969968 
in Asians compared with whites (0.03 vs 0.3; Table 3) and the high 
proportion of Asian never-smokers (40% of the case patients and Ta
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Table 6. Association between the risk of lung cancer and the 
number of risk alleles combining genotypes of rs402710, 
rs2736100, and rs16969968 in whites*
Number of  
risk alleles
Case  
patients  
(n = 7964)
Control  
subjects  
(n = 8212) OR (95% CI) P
0 95 153 1.00 (referent)
1 551 765 1.16 (0.87 to 1.55) .32
2 1538 1856 1.30 (0.98 to 1.71) .06
3 2364 2458 1.53 (1.16 to 2.01) .003
4 2097 1955 1.72 (1.30 to 2.26) 1 × 1024
5 1099 883 1.98 (1.49 to 2.63) 2 × 1026
6 220 142 2.64 (1.86 to 3.74) 4 × 1028
Per risk allele 1.15 (1.12 to 1.18) 1 × 10226
* P values (two-sided) were from logistic regression. CI = confidence interval; 
OR = odds ratio.
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60% of the control subjects) may partially explain these negative 
findings. We also lack any a priori evidence that the genetic 
markers at 15q25 that we chose to study are relevant in Asians. 
However, other studies in Asian populations have reported lung 
cancer susceptibility loci at chromosome 15q25. For example, a 
Japanese case–control study (28) reported an association between 
rs16969968 and the risk of lung cancer (OR = 2.2, 95% CI = 1.5 to 
3.4, P = 1.5 × 1024), and similar associations were observed among 
never-smokers (OR = 2.4, 95% CI = 1.2 to 4.7, P = .013) and ever-
smokers (OR = 2.2, 95% CI = 1.1 to 4.1, P = .016). Although the 
minor allele frequency of rs16969968 in the Japanese study popu-
lation was, as expected, very low (0.015), the proportion of never-
smokers among the case patients was lower than that in our study 
(21% vs 40%). Another large study conducted in China (29) iden-
tified statistically significant associations between four novel SNPs 
in the 15q25 region and age at lung cancer diagnosis and smoking 
behavior, whereas none of these associations was reported for the 
15q25 SNPs that were previously reported in whites. The associa-
tions between the four novel SNPs and the risk of lung cancer 
were substantially stronger in younger age at diagnosis patients, 
similar to our findings in white populations, and were consistent 
among never-smokers and smokers (29). The latter observation 
argues strongly for a role of the 15q25 locus in lung cancer that is 
independent of smoking behavior in Asians.
This replication analysis provided conclusive evidence for asso-
ciations between rs2736100 and rs402710 at chromosome 5p15 
and susceptibility to lung cancer in both whites and Asians. These 
associations appeared to be independent because restricting the 
analysis to homozygous carriers of common alleles of one variant 
did not alter the association of the other variant. This finding may 
also suggest the existence of an unknown variant that is in linkage 
disequilibrium with rs2736100 and rs402710 that captures the 
effect of both rs2736100 and rs402710. In contrast with the 
chromosome 15q25 findings, both SNPs at chromosome 5p15 
were associated with statistically significant increased risks of lung 
cancer in never-smokers as well as in ever-smokers, and there were 
no patterns of association by age at diagnosis or duration of 
smoking for either ethnic group.
These results were in accordance with those reported by pre-
vious genome-wide association studies in a white population. 
McKay et al. (4) reported odds ratios of 1.14 for rs2736100 and 
1.18 for rs402710, whereas Wang et al. (5) reported an odds ratio 
of 1.14 for rs401681 (in strong linkage disequilibrium with 
rs402710). Neither of these studies reported heterogeneity by 
histology, smoking status, age at diagnosis, or sex. The magnitudes 
of these associations are consistent with our findings. However, 
associations between these variants and the risk of lung cancer 
differed by histology, and this finding was consistent in both ethnic 
groups. In particular, we identified an increased risk for adenocar-
cinomas for both variants in both whites and Asians and an absence 
of any risk for small-cell carcinomas. Squamous and large-cell 
carcinomas gave intermediate results. Another study conducted in 
Iceland (6) found associations between rs401681, located in the 
CLPTM1L gene, and several smoking-related cancers, including 
lung cancer (P = 7 × 1028), as well as cancers of the bladder, pros-
tate, skin, and cervix. They also noted that rs2736098, which is 
located in the TERT gene at 5p15, showed a stronger association 
with lung cancer (P = 3 × 1025), bladder and prostate cancers, and 
basal cell carcinomas.
In a case–control study conducted in a Chinese population, Jin 
et al. (30) reported that rs2736100 was associated with an increased 
risk of non–small cell lung carcinomas, with odds ratios of 1.26 
(95% CI = 1.05 to 1.51) and 1.31 (95% CI = 1.04 to 1.66) for one 
and two copies of the variant C allele, respectively. They noted 
that the association was more prominent among women (Pheterogeneity = 
.044), nonsmokers (Pheterogeneity = .054), and patients with adenocar-
cinoma (Pheterogeneity = .058). Our data suggested that the association 
between rs2736100 and the risk of lung cancer was strongest for 
adenocarcinoma and that the difference between males and females 
was at least partially explained by the higher proportion of adeno-
carcinoma among women.
rs2736100 and rs402710 were also previously found to be asso-
ciated with other diseases. rs2736100 was found to be associated 
with glioma susceptibility in two recent genome-wide association 
studies (31,32) conducted in whites. Another genome-wide associ-
ation study conducted in a Japanese population found that this 
SNP was associated with idiopathic pulmonary fibrosis (33).
TERT encodes the enzyme telomerase reverse transcriptase, 
which is the catalytic subunit of telomerase that adds telomeric 
repeat sequences onto chromosome ends (34). High expression of 
telomerase is commonly observed in lung cancer, which suggests 
that TERT may have a critical role in lung tumorigenesis (35–37). 
An association between short telomeres and an increased risk of 
cancer has been reported for several types of cancers, including 
basal cell carcinoma, cancers of the lung, head and neck, bladder, 
kidney, esophagus, and breast, as well as lymphoma (6,38–42). 
Rafnar et al. (6) reported that rs401681 and rs2736098 were asso-
ciated with shorter telomere length in older healthy women but 
not in younger healthy women and suggested that these variants 
may lead to an increase in the gradual shortening of telomeres over 
time. Zhu et al. (43) reported that TERT gene amplification is 
more commonly seen in adenocarcinoma than in squamous cell 
carcinoma and that overexpression of TERT mRNA is correlated 
with TERT gene amplification in adenocarcinoma but not in squa-
mous cell carcinoma. Zhu et al. hypothesized that overexpression 
of TERT mRNA in adenocarcinomas is largely due to TERT am-
plification, whereas in other lung tumor types, it is mainly con-
trolled by epigenetic factors. Our data are in accordance with these 
findings.
Concerning the variants at chromosome 6p21, the associations 
with rs2256543 and rs4324798 were not replicated in whites in this 
study. It should be noted that for this replication analysis, we se-
lected the two most statistically significant variants from the IARC 
genome-wide association study (4). The borderline statistically 
significant associations we reported may indicate that other SNPs 
in this region may be better candidates than the ones we selected. 
For example, Wang et al. (5) reported associations between two 
6p21 variants—rs3117582 in BAT3 and rs3131379 in MSH5—that 
are located approximately 3 Mb away from the 6p21 variants ana-
lyzed in this study. These two SNPs are highly correlated (r2 = 
.99), and the genes in which they reside are strong candidates for 
lung cancer susceptibility loci: BAT3 is implicated in apoptosis 
(44), and MSH5 is involved in DNA mismatch repair (45). Further 
investigation of this region is warranted.
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This study has several limitations. First, we selected variants 
that were found to be associated with lung cancer in genome-wide 
association studies that were conducted in whites. Replication of 
these variants in Asians may not be relevant. As we reported in this 
study, the variants we selected at chromosome 15q25 (rs16969968 
and rs8034191) had a very low minor allele frequency in Asians. 
Three other variants at 15q25 were therefore selected for this 
population, albeit with a lack of a priori evidence, and were also 
not replicated. Second, many different studies with different geno-
typing protocols were included in this study, which could have lead 
to heterogeneity. However, we implemented stringent interlabo-
ratory quality control procedures in all centers and found no evi-
dence of any such heterogeneity by study.
In conclusion, this analysis exemplifies the timely and cost- 
effective contributions that international consortia can provide to 
genome-wide association replication studies. Our observations of 
heterogeneity by histology of associations between variants at 5p15 
and the risk of lung cancer are particularly notable and indicate 
that further study of the role of this locus in lung cancer develop-
ment is warranted. Future lung cancer genome-wide association 
studies should routinely include histology-specific analyses.
Supplementary Data
Supplementary data can be found at http://www.jnci.oxfordjournals 
.org/.
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